Purpose: To evaluate the age- and gender-specific prevalence of early and late age-related macular degeneration (AMD) in a Portuguese population-based sample. Methods: All patients aged ≥55 years of a Portuguese primary health-care unit were recruited for a cross-sectional population-based study. Responders underwent complete ophthalmological examination and digital fundus imaging. Early and late AMD was defined according to the International Age-Related Macular Epidemiological Study Group Classification, and the adopted staging for AMD was the same as that used in the Rotterdam study. The age- and gender-adjusted prevalence of early and late forms of AMD was calculated. Results: Of the 4,370 eligible subjects, 3,000 underwent study procedures (68.6% response rate) and 2,975 were included in the analysis; they had a mean age of 68.9 ± 8.6 years. The overall prevalence of early and late AMD was 15.53% (95% CI 14.25-16.88) and 0.67% (95% CI 0.41-1.04), respectively. Neovascular AMD (NV-AMD) and geographic atrophy (GA) accounted for 0.44% (95% CI 0.23-0.75) and 0.27% (95% CI 0.12-0.53) of individuals, respectively. The highest prevalence of advanced AMD was among those aged ≥75 years (1.13% for NV-AMD; 0.63% for GA). Conclusions: To our knowledge, this is the first AMD epidemiological study in a Portuguese population. The early forms of the disease had a similar prevalence to that of other large-scale population-based cohorts, but late AMD was less frequent than previously reported.

Keywords:
Age-related macular degeneration, Neovascular age-related macular degeneration, Geographic atrophy
1.
Tomany SC, et al: Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-1287.
2.
Bird AC, et al: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-374.
3.
Klein R, et al: The Wisconsin age-related maculopathy grading system. Ophthalmology 1991;98:1128-1134.
4.
Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol 2001;119:1417-1436.
5.
Liu MM, Chan CC, Tuo J: Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics 2012;6:13.
6.
Smith W, et al: Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704.
7.
Klein R: Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007;14:184-187.
8.
Hogg RE, et al: Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008;115:1046-1052.e2.
9.
Snow KK, Seddon JM: Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 1999;6:125-143.
10.
Friedman DS, et al: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106:1049-1055.
11.
Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
12.
Bressler SB, et al: Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol 2008;126:241-245.
13.
Klein R, et al: Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol 1999;117:1203-1210.
14.
Klein R, et al: Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110:25-33.
15.
Klein R, et al: Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006;113:373-380.
16.
Mitchell P, et al: Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-1460.
17.
VanNewkirk MR, et al: The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000;107:1593-1600.
18.
Vingerling JR, et al: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-210.
19.
Augood CA, et al: Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006;124:529-535.
20.
Topouzis F, et al: Prevalence of age-related macular degeneration in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2006;142:1076-1079.
21.
Jonasson F, et al: The prevalence of age-related maculopathy in Iceland: Reykjavik Eye Study. Arch Ophthalmol 2003;121:379-385.
22.
Delcourt C, et al: Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age. Arch Ophthalmol 1998;116:1031-1035.
23.
Delcourt C, et al: Nutrition and age-related eye diseases: the Alienor (Antioxydants, Lipides Essentiels, Nutrition et maladies OculaiRes) Study. J Nutr Health Aging 2010;14:854-861.
24.
Friedman DS, et al: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
25.
Li Y, et al: Prevalence of age-related maculopathy in the adult population in China: the Beijing Eye Study. Am J Ophthalmol 2008;146:329.
26.
Chen SJ, et al: Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 2008;49:3126-3133.
27.
Erke MG, et al: Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso Eye Study. Ophthalmology 2012;119:1737-1743.
28.
Piermarocchi S, et al: The prevalence of age-related macular degeneration in Italy (PAMDI) study: report 1. Ophthalmic Epidemiol 2011;18:129-136.
29.
Davis MD, et al: The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484-1498.
30.
Ferris FL, et al: A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123:1570-1574.
31.
Seddon JM, Sharma S, Adelman RA: Evaluation of the clinical age-related maculopathy staging system. Ophthalmology 2006;113:260-266.
32.
Ferris FL 3rd, et al: Clinical classification of age-related macular degeneration. Ophthalmology 2013;120:844-851.
33.
Marques JP, et al: Ocular risk factors for exudative AMD: a novel semiautomated grading system. ISRN Ophthalmol 2013;2013:464218.
34.
Jonasson F, et al: Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study. Ophthalmology 2011;118:825-830.
35.
van Leeuwen R, et al: The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam Study. Arch Ophthalmol 2003;121:519-526.
36.
Pagliarini S, et al: Age-related macular disease in rural southern Italy. Arch Ophthalmol 1997;115:616-622.
37.
Rudnicka AR, et al: Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012;119:571-580.
38.
Thornton J, et al: Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005;19:935-944.
39.
Chakravarthy U, et al: Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 2007;114:1157-1163.
40.
Khan JC, et al: Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006;90:75-80.
41.
Tan JS, et al: Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2007;125:1089-1095.
42.
Mitchell P, et al: Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 2002;120:1357-1363.
43.
Klein R, et al: Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol 2002;156:589-598.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.